| Issue Date | Title | Author(s) |
| Jun-2023 | Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer | Lei, Huizi; Ling, Yun; Yuan, Pei; Yan, Xieqiao; Wang, Lin; Shi, Yanxia; Yao, Xin; Luo, Hong; Shi, Benkang; Liu, Jiyan; He, Zhisong; Yu, Guohua; Han, Weiqing; Hu, Changlu; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Fang, Jianmin; Guo, Jun; Sheng, Xinan; Zhou, Aiping; Ying, Jianming |
| 2019 | Author's Reply to Puertolas-Tena and Perez-Surio: "Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis" | Yang, Jichun; Yu, Shuqing; Yang, Zhirong; Yan, Yusong; Chen, Yao; Zeng, Hongmei; Ma, Fei; Shi, Yanxia; Shi, Yehui; Zhang, Zilu; Sun, Feng |
| 2019 | Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Yang, Jichun; Yu, Shuqing; Yang, Zhirong; Yan, Yusong; Chen, Yao; Zeng, Hongmei; Ma, Fei; Shi, Yanxia; Shi, Yehui; Zhang, Zilu; Sun, Feng |
| 2019 | Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis | Yang, Jichun; Yu, Shuqing; Yang, Zhirong; Yan, Yusong; Chen, Yao; Zeng, Hongmei; Ma, Fei; Shi, Yanxia; Shi, Yehui; Zhang, Zilu; Sun, Feng |
| 2019 | Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis (vol 33, pg 373, 2019) | Yang, Jichun; Yu, Shuqing; Yang, Zhirong; Yan, Yusong; Chen, Yao; Zeng, Hongmei; Ma, Fei; Shi, Yanxia; Shi, Yehui; Zhang, Zilu; Sun, Feng |
| 2015 | Identification of Green Tea Catechins as Potent Inhibitors of the Polo-Box Domain of Polo-Like kinase 1 | Shan, Hong-Mei; Shi, Yanxia; Quan, Junmin |
| 2011 | Molecular design, synthesis and bioactivity of glycosyl hydrazine and hydrazone derivatives: Notable effects of the sugar moiety | Cui, Zining; Yang, Xinling; Shi, Yanxia; Uzawa, Hirotaka; Cui, Jingrong; Dohi, Hirofumi; Nishida, Yoshihiro |
| 2015 | A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase | Zuo, Yingying; Shi, Yanxia; Li, Xitao; Teng, Yingqi; Pan, Zhengying |
| 1-Jan-2021 | Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma | Sheng, Xinan; Yan, Xieqiao; Wang, Lin; Shi, Yanxia; Yao, Xin; Luo, Hong; Shi, Benkang; Liu, Jiyan; He, Zhisong; Yu, Guohua; Ying, Jianming; Han, Weiqing; Hu, Changlu; Ling, Yun; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Fang, Jianmin; Zhou, Aiping; Guo, Jun |
| 20-May-2021 | An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009). | Sheng, Xinan; He, Zhisong; Han, Weiqing; Zhou, Ai-Ping; Luo, Hong; Shi, Yanxia; Hu, Changlu; Liu, Ziling; Guo, Hongqian; Yao, Xin; Shi, Benkang; Liu, Jiyan; Ji, Zhigang; Guo, Jianming; Hu, Yi; Yu, Shi Ying; Yu, Guohua; Ying, Jianming; Fang, Jianmin; Guo, Jun |
| 2019 | A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. | Sheng, Xinan; Zhou, Ai-Ping; Yao, Xin; Shi, Yanxia; Luo, Hong; Shi, Benkang; Liu, Jiyan; Yu, Guohua; He, Zhisong; Hu, Changlu; Han, Weiqing; Fang, Jianmin; Guo, Jun |
| 1-Jun-2022 | RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. | Sheng, Xinan; He, Zhisong; Shi, Yanxia; Luo, Hong; Han, Weiqing; Yao, Xin; Shi, Benkang; Liu, Jiyan; Hu, Changlu; Liu, Ziling; Guo, Hongqian; Yu, Guohua; Ji, Zhigang; Yu, Shiying; Hu, Yi; Guo, Jianming; Ying, Jianming; Fang, Jianmin; Zhou, Aiping; Guo, Jun |
| 2010 | Synthesis and Bioactivity of N-Benzoyl-N '-[5-(2 '-substituted phenyl)-2-furoyl] Semicarbazide Derivatives | Cui, Zining; Ling, Yun; Li, Baoju; Li, Yongqiang; Rui, Changhui; Cui, Jingrong; Shi, Yanxia; Yang, Xinling |
| 2-Nov-2023 | Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical AntiLeukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations | Shi, Yanxia; Jiang, Qian; Li, Linxin; Jiang, Shuzhen; Yan, Tingting; Zheng, Cuifang; Ai, Yixin; Wang, Yihan |
